NIP
RVNC

Nicholas Investment Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Nicholas Investment Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-113,090
Closed -$4.04M – 263
2017
Q4 		$4.04M Buy
+113,090
New +$3.25M 0.27% 116
2014
Q4 		– Sell
-92,288
Closed -$1.78M – 322
2014
Q3 		$1.78M Buy
92,288
+32,033
+53% +$835K 0.11% 255
2014
Q2 		$2.05M Buy
+60,255
New +$1.89M 0.12% 233

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Nicholas Investment Partners's RVNC Position: Q1 2018 in Review

Nicholas Investment Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2018, closing a stake of 113,090 shares — an estimated $4.04M sold.

Nicholas Investment Partners first reported a position in RVNC in Q2 2014 and held it in 3 quarters. The position peaked at $4.04M in Q4 2017. 120 funds tracked by Wall St. Rank hold RVNC as of Q1 2018.

  • Nicholas Investment Partners reported no remaining Revance Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Nicholas Investment Partners sold 113,090 Revance Therapeutics, Inc. shares in Q1 2018, an estimated $4.04M.
  • Nicholas Investment Partners first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 3 quarters.
  • Nicholas Investment Partners's Revance Therapeutics, Inc. position peaked at $4.04M in Q4 2017.
  • 120 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2018.

Based on Nicholas Investment Partners's 13F filing for Q1 2018, filed 15 May 2018.